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ttp://dx.doi.org/10.1016/j.ajpath.2014.01.025The chemotherapeutic drug cisplatin is actively transported into proximal tubules, leading to acute
renal injury. Previous studies suggest that the multidrug resistanceeassociated protein 2 (Mrp2)
transporter may efﬂux cisplatin conjugates from cells. We sought to determine whether the absence of
Mrp2 alters the accumulation and toxicity of platinum in the kidneys of mice and whether transgenic
expression of the human MRP2 gene could protect against cisplatin injury in vivo. Plasma, kidneys, and
livers from vehicle- and cisplatin-treated wild-type and Mrp2-null mice were collected for quantiﬁcation
of platinum and toxicity. By 24 hours, twofold higher concentrations of platinum were detected in the
kidneys and livers of Mrp2-null mice compared with wild types. Enhanced platinum concentrations in
Mrp2-null mice were observed in DNA and cytosolic fractions of the kidneys. Four days after cisplatin
treatment, more extensive proximal tubule injury was observed in Mrp2-null mice compared with wild-
type mice. Kidneys from naive Mrp2-null mice had elevated glutathione S-transferase mRNA levels,
which could increase the formation of cisplatin-glutathione conjugates that may be metabolized to
toxic thiol intermediates. Transgenic expression of the human MRP2 gene in Mrp2-null mice reduced the
accumulation and nephrotoxicity of cisplatin to levels observed in wild-type mice. These data suggest
that deﬁciency in Mrp2 lowers platinum excretion and increases susceptibility to kidney injury, which
can be rescued by the human MRP2 ortholog. (Am J Pathol 2014, 184: 1299e1308; http://dx.doi.org/
10.1016/j.ajpath.2014.01.025)Supported by National Institute of Diabetes and Digestive and Kidney
Diseases grants DK080774 and DK093903 (L.M.A.), National Institute of
Environmental Health Sciences grants ES020522 and ES005022, compo-
nents of the National Institutes of Health, and by the Pharmacokinetics and
Pharmacodynamics Shared Resource of The Cancer Institute of New Jersey
(grant CA072720). A portion of this work was supported by startup funding
from the Environmental and Occupational Health Sciences Institute.
Disclosures: None declared.Cisplatin is commonly used in chemotherapy regimens for
the treatment of solid cancers. The success of cisplatin ther-
apy is limited, in part, by kidney injury. Up to 37% of patients
develop signs of nephrotoxicity after receiving a single dose
of cisplatin despite strategies such as hydration to limit renal
exposure.1 This is problematic for patients because kidney
injury can delay further treatment and limit the total number
of chemotherapy cycles received, thereby reducing the
overall efﬁcacy of cisplatin-containing regimens.
Previous studies have identiﬁed the contribution of uptake
and efﬂux transporters to the renal secretion of cisplatin.
The organic cation transporter 2 (Oct2; gene Slc22a2) is
highly expressed in the kidneys andmediates the renal uptake
of cisplatin.2e5 Transgenic mice lacking Oct1 and Oct2stigative Pathology.
.transporters exhibit decreased platinum (Pt) excretion and
reduced nephrotoxicity.6 In addition, patients with cancer
with a loss-of-function polymorphism in OCT2 (808G>T)
are protected against cisplatin renal injury.6,7 Additional data
suggest that the copper transporter 1 (Ctr1; gene Slc31a1)
participates in the renal uptake of cisplatin,8e12 although
Table 1 Methods for Inductively Coupled Plasma Mass Spectrometry Analysis
Matrix
Approximate weight (g)
or volume (mL) Nitric acid (mL) Microwave program, 300 W
Urine* 20e100 mL 0.25e0.5 50% power, 5 minutes, once, then 75% power, 5 minutes, 5
Liveryz 0.1e0.25 g 1e1.5 75% power, 5 minutes, once, then 100% power, 5 minutes, 5,
then 100% power, 10 minutes, 1e2
Kidneyy 0.1e0.25 g 1e1.5 Same as liver
Plasma*yx 50 mL 0.25 Same as urine
Vesicles 100 mL 0.15 Same as urine
*The approximate rule for a largely aqueous matrix is at least two parts acid to one part matrix by volume.
yMicrowaving was discontinued when the samples were clear and pale yellow.
zHydrogen peroxide (0.5 mL, 30% H2O2) was occasionally added to complete the digestion of liver. If so, an additional microwave treatment (100% power,
10 minutes) was used to decompose the residual hydrogen peroxide.
xSamples in the 0.25-mL range can be microwaved in 15-mL centrifuge tubes provided that less time and lower percentage power are used.
Figure 1 Interaction of mMrp2 and hMRP2 transporters with cisplatin
in vitro. A: Western blot analysis of commercially available mMrp2 and
hMRP2 vesicles. b-Actin was used as a loading control. B: Twenty micro-
grams of inverted Mrp2- and MRP2-expressing vesicles were incubated with
10 mmol/L CDCF for 10 minutes in the presence and absence of adenosine
triphosphate (ATP), GSH, and increasing concentrations of cisplatin. The
total mean transport rates of CDCF in mMrp2- and hMRP2-expressing ves-
icles were 1051 and 1933 pmol/min/mg of protein, respectively (data not
shown). The ATP-independent transport rates of CDCF in mMrp2- and
hMRP2-expressing vesicles were 12 and 222 pmol/min/mg protein,
respectively (data not shown). Data are presented as means  SEM (nZ 4
to 5) normalized to ATP-dependent MRP2 transport of CDCF (no cisplatin).
*P < 0.05 compared with 0 mmol/L cisplatin.
Wen et alrecent work has found conﬂicting results.13 After uptake of
cisplatin by Oct2 or Ctr1, the subsequent efﬂux of cisplatin
into the renal lumen is mediated by the multidrug and toxin
extrusion protein 1 (Mate1; gene Slc47a1).14 As expected,
Mate1 knockout mice have increased renal concentrations of
cisplatin and enhanced nephrotoxicity.14
Once inside the renal cell, cisplatin is biotransformed by
spontaneous hydrolysis to monoaquated and diaquated spe-
cies. Formation of cisplatin aquated intermediates leads to
electrophilic attack of cellular macromolecules, such as DNA
and protein. The tripeptide glutathione (GSH) can also
bind cisplatin and has been suggested to form a variety of
nontoxic cisplatin conjugates, including monoplatinum-
monoglutathione, diplatinum-monoglutathione, and bis-
(glutathionato)-platinum.15,16 It has been postulated that
these conjugates have the potential for metabolism to reactive
thiol intermediates. Previous studies suggest that the multi-
drug resistanceeassociated transporter 2 (Mrp2; gene Abcc2)
can efﬂux GSH conjugates of cisplatin from cancer cells and
confer resistance to cytotoxicity.15,17,18 Overexpression of
human (h)MRP2 increases cisplatin resistance by 10-fold in
human embryonic kidney cells17 and reduces cisplatin
accumulation by 30% in porcine kidney LLC-PK1 cells.18
Moreover, primary hepatocytes isolated from transport-
deﬁcient rats (Mrp2-deﬁcient strain) exhibit increased bind-
ing of Pt to DNA and enhanced susceptibility to cisplatin
cytotoxicity.19 However, the ability of Mrp2 to reduce the
accumulation of cisplatin and/or its conjugates and limit renal
injury in vivo is not well understood. Therefore, the purpose
of this study was to determine whether loss of Mrp2 function
enhances renal Pt accumulation and nephrotoxicity in mice
and to evaluate the ability of the humanMRP2 gene to rescue
Mrp2-null mice from heightened cisplatin-induced nephro-
toxicity in vivo.
Materials and Methods
Chemicals
Unless otherwise speciﬁed, all chemicals were obtained
from Sigma-Aldrich (St. Louis, MO).1300Vesicle Transport Assays
Inside-out Sf9 insect cell plasma membrane vesicles ex-
pressing mouse (m)Mrp2 or hMRP2 were purchased from
Life Technologies (Carlsbad, CA). To assess the ability of
cisplatin to inhibit Mrp2/MRP2-mediated transport of 5,6-
carboxy-20,70-dichloroﬂuorescein (CDCF), 20-mg vesicles
were incubated with 10 mmol/L CDCF, 4 mmol/L adenosine
triphosphate, 2 mmol/L GSH, and increasing concentrations
of cisplatin (50 to 200 mmol/L) in reaction buffer at 37C for
10 minutes according to the manufacturer’s protocol. Ves-
icles were washed, vacuum ﬁltered, and solubilized with
50% methanol. Fluorescence was read at excitation wave-
length 504 nm; emission wavelength 529 nm.ajp.amjpathol.org - The American Journal of Pathology
Figure 2 Renal and hepatic injury markers in wild-type (black bars) and Mrp2-null (gray bars) mice treated with cisplatin. A: BUN, serum creatinine (SCr),
and alanine aminotransferase (ALT) levels in plasma from WT and Mrp2-null mice 2 through 4 days after 20 mg/kg of i.p. cisplatin treatment (nZ 5 to 15). B:
mRNA expression of kidney injury molecule-1 (Kim-1), metallothionein-1 (Mt-1), and heme oxygenase-1 (Ho-1) was quantiﬁed using total kidney RNA from
control and 20-mg/kg cisplatin-treated WT and Mrp2-null mice on day 4 (nZ 4 to 11). C: Urine ﬂow rate of control and 20-mg/kg cisplatin-treated WT and
Mrp2-null mice from day 3 to 4. Urine volume was quantiﬁed from mice in metabolic cages for 24 hours and was normalized to body weight (nZ 3 to 8). Data
are presented as means  SEM. mRNA data were normalized to WT control mice. *P < 0.05, compared with genotype control mice; yP < 0.05, compared with
cisplatin-treated WT mice.
Figure 3 Histopathologic injury in WT and Mrp2-null mice treated with
cisplatin. WT and Mrp2-null mice were treated with vehicle or 20 mg/kg of
i.p. cisplatin, and kidneys were collected on day 4. Samples were ﬁxed in
zinc formalin before routine processing and parafﬁn embedding. Five-
micron sections of kidneys were stained with H&E and were examined by
light microscopy for the presence and severity of renal cast formation (*),
proximal tubule degeneration (þ), apoptosis, and necrosis (^) as well as
neutrophil inﬁltration. Original magniﬁcation, 40.
MRP2 Protects Against Cisplatin ToxicityAnimal Treatment
Wild-type (WT) C57BL/6 mice were purchased from
Charles River Laboratories (Wilmington, MA). Mrp2-null
mice were obtained from Taconic Laboratories (Hudson,
NY) and were backcrossed until they were >99% congenic
with the C57BL/6 strain. Congenic analysis was performed
by the Bionomics Research and Technology Core at Rutgers
University (New Brunswick, NJ). hMRP2 mice on a
C57BL/6 background were purchased from Taconic.
Cisplatin was dissolved in saline after heating to 50C.
Groups of 9- to 14-week-old adult male mice were injected
i.p. with 5 mL/kg of saline vehicle or 20 mg/kg of cisplatin
after overnight fasting. The doses of cisplatin used in this
study were similar to those used clinically.1 Feed was
returned 4 hours after cisplatin injection. Kidney, liver, and
plasma samples were collected 1 hour to 4 days after
cisplatin treatment. Groups of mice were placed into meta-
bolism cages for quantiﬁcation of urine Pt concentrations
(24-hour periods between 0 and 3 days) and urine output
(24-hour period from 3 to 4 days). Tissues were ﬁxed in
10% formalin or were snap frozen.
Analytes and Pathology
Blood urea nitrogen (BUN) and serum creatinine levels were
quantiﬁed as indicators of renal injury (Thermotrace, Mel-
bourne, Australia; and Pointe Scientiﬁc, Canton, MI). Total
and direct bilirubin concentrations as well as alanine
aminotransferase activity were also quantiﬁed (Pointe Sci-
entiﬁc). GSHwas quantiﬁed using the GSH/GSSG-Glo assay
(Promega, Madison, WI). Five-micron parafﬁn-embedded
kidney sections were stained with H&E and were examinedThe American Journal of Pathology - ajp.amjpathol.orgfor histopathological changes by a board-certiﬁed anatomic
veterinary pathologist (M.J.G.) using a published grading
scale.20RNA Isolation and mRNA Quantiﬁcation
Total RNA was isolated using RNA-Bee reagent (Tel-
Test Inc., Friendswood, TX). The mRNA expression of
mouse kidney injury molecule-1, heme oxygenase-1,1301
Figure 4 Pt concentrations in WT and Mrp2-null mice treated with
cisplatin. Quantiﬁcation of Pt concentrations by inductively coupled plasma
mass spectrometry in the kidneys, livers, plasma, and urine (A) and cytosol,
crude membrane, and DNA fractions from kidneys (B) of WT and Mrp2-null
mice treated with 20 mg/kg of i.p. cisplatin. There were no differences in
urine output between WT and Mrp2-null mice up to 72 hours. Data are
presented as means  SEM. n Z 4 to 10 (A); n Z 5 (B). *P < 0.05
compared with cisplatin-treated WT mice.
Table 2 Histopathologic Analysis of Kidneys from WT and Mrp2-
Null Mice after Cisplatin Injection
Mice and
time after
injection
Histopathologic grade Mice with
grade
2 (%)0 1 2 3 4 5
WT
Control 13 0 0 0 0 0 0
2 Days 1 6 0 0 0 0 0*
3 Days 1 2 2 0 0 0 40*
4 Days 4 3 6 1 0 0 50*
Mrp2-null
Control 13 0 0 0 0 0 0
2 Days 1 4 2 0 0 0 29*
3 Days 1 1 3 0 0 0 60*
4 Days 0 1 3 6 2 0 91*y
Kidneys were removed 2 to 4 days after 20 mg/kg of i.p. cisplatin or vehicle
injection andwereﬁxed in zinc formalin beforeparafﬁn embeddingand staining
with H&E. Kidney slices were evaluated for the severity of degeneration and
necrosis in proximal tubule segments. Histopathologic scoring of renal proximal
tubule degeneration and necrosis by a veterinary pathologist was as follows:
grade 0, no injury; grade 1, minimal injury involving <10% of cells with
degeneration or necrosis; grade 2, mild injury involving 10% to 25% of cells;
grade 3,moderate injury involving>25% to 40%of cells; grade 4,marked injury
involving>40% to 50% of cells; grade 5, severe injury involving>50% of cells.
The number of mice with a particular histopathologic grade is shown in each
column. Mice with grades 2 are considered to have signiﬁcant kidney injury.
The ratios of mice with grades2 compared with the total number of mice are
presented as percentages. Histopathologic grades were rank ordered before
statistical analysis.
*P < 0.05 compared with genotype control mice.
yP < 0.05 compared with cisplatin-treated WT mice.
Wen et almetallothionein-1, glutathione S-transferase (Gst) iso-
forms, glutamate cysteine ligase catalytic subunit, Oct2,
Mrp4, breast cancer resistance protein (Bcrp), and
multidrug resistance protein 1a was quantiﬁed using the
branched DNA 1.0 signal ampliﬁcation assay (Affymetrix
Inc., Santa Clara, CA).21 Oct1, Mate1, and Ctr1 mRNAs
were quantiﬁed by quantitative PCR. cDNA was gener-
ated using the SuperScript ﬁrst-strand cDNA synthesis kit
(Life Technologies). Speciﬁc forward and reverse primers
(Integrated DNA Technologies, Coralville, IA) were
added to 1 mg of cDNA from each sample. The following
primers (forward and reverse, respectively) were used for
mouse Mate1 (50-GTTGGCCTTACGGAGAGGAC-30
and 50-AATCCCACCCACCAAGACTAA-30), mouse
Ctr1 (50-ACACACAAAACTGTTGGGCAG-30 and 50-
AGAGAAAGTATCCCGTCCCAG-30), mouse Oct1 (50-
TGTCGGCTCTGGCTACAGGAGA-30 and 50-GGGGG-
ATTCTGGGACAAACCAGTAA-30), and mouse ribosomal
protein l 13a (Rpl13a) (50-CAAGAAAAAGCGGATGGT-
GG-30 and 50-TCCGTAACCTCAAGATCTGC-30). SYBR
Green (Applied Biosystems, Carlsbad, CA) was used for the
detection of ampliﬁed products. Quantitative PCR was per-
formed in a 384-well plate format using the ABI 7900HT
PCR system (Applied Biosystems). CT values were con-
verted to DDCT values by comparing with a reference gene,
Rpl13a.1302Inductively Coupled Plasma Mass Spectrometry
Total Pt Analysis
Concentrated EMD OmniTace Ultra high-purity nitric acid
(VWR, Radnor, PA) was added to all the samples to a ﬁnal
concentration of 5%, followed by digestion using a CEM
Mars X microwave system (CEM Corp, Matthews, NC)
(Table 1). Large samples were pretreated in an ultrasonic
bath, whereas samples not completely digested were reac-
ted, postdigestion, with 30% hydrogen peroxide (Trace-
Select, Fluka; Sigma-Aldrich). Digested samples were
analyzed by inductively coupled plasma mass spectrometry
using a Thermo-Elemental X5 instrument (Thermo Fisher).
Multiple Pt ions were monitored for quality control. Re-
ported concentrations were determined using m/z Z 195.
This method has been used previously for metals analysis in
blood samples.22
Fractionation Pt Studies
Kidneys were homogenized in 250 mmol/L sucrosee10
mmol/L Tris buffer and were centrifuged at 100,000  g for
the collection of cytosol and crude membrane fractions.
DNA was isolated using the DNeasy blood and tissue kit
(Qiagen, Valencia, CA).ajp.amjpathol.org - The American Journal of Pathology
MRP2 Protects Against Cisplatin ToxicityWestern Blot Analysis
Kidneys were homogenized in sucrose-Tris buffer contain-
ing protease inhibitors. Western blot staining was performedThe American Journal of Pathology - ajp.amjpathol.orgas described elsewhere.23 The following antibodies were
used: Mrp2 (M2III-5), Mrp4 (M4I-10), and Bcrp (BXP-53)
fromEnzoLife Sciences (Farmingdale,NY);Oct2 (sc292622)
andMate1 (sc138983) from Santa Cruz Biotechnology (Santa
Cruz, CA); and Ctr1 (ab129067), multidrug resistance protein
1a/b (C219), and b-actin (ab8227) from Abcam Inc. (Cam-
bridge, MA).
Immunoﬂuorescence
Immunoﬂuorescence analysis was performed for hMRP2
(M2III-6), mMrp2 (EAG15), and mouse Bcrp (Bxp-53).
Sections were washed and incubated with goat anti-mouse
or anti-rabbit IgG Alexa 488 IgG and anti-rat 563 IgG an-
tibodies (Invitrogen, Carlsbad, CA). Images were acquired
using a Zeiss Observer D1 microscope with an X-Cite series
120Q ﬂuorescent illuminator (Zeiss Inc., Thornwood, NY)
and a ProgRes camera with CapturePro version 2.8 software
(Jenoptik, Easthampton, MA). Negative controls without
primary antibody were included to ensure minimal nonspe-
ciﬁc staining (data not shown).
Statistical Analysis
The software program GraphPad Prism version 5 (Graph-
Pad Software Inc., La Jolla, CA) was used for statistical
analysis. Pharmacokinetic curves were generated using
area-under-the-curve analysis with one-phase nonlinear
decay. Differences among groups were evaluated by Stu-
dent’s unpaired t-test (two groups) or one-way analysis of
variance followed by the Newman-Keuls multiple com-
parison tests (three or more groups). Histopathological data
were rank ordered before analysis. Statistical signiﬁcance
was set at P < 0.05.
Results
Interaction of mMrp2 and hMRP2 Transporters with
Cisplatin in Vitro
An indirect approach (competition for transport) was used to
investigate cisplatin as a potential Mrp2/MRP2 substrate in
the presence of GSH using inverted plasma membrane ves-
icles. Commercial vesicles expressed the Mrp2 and MRP2
proteins, with notably lower expression of mMrp2 compared
with hMRP2 protein (Figure 1A). The probe Mrp2/MRP2
substrate, CDCF, was used for inhibition assays as pre-
viously described.24,25 Cisplatin inhibited the adenosineFigure 5 Basal expression of transporters and GSH-related enzymes in
kidneys of naive WT and Mrp2-null mice. A: mRNA levels of uptake and
efﬂux transporters in WT and Mrp2-null mice. B: Western blot analysis of
transporter proteins in WT and Mrp2-null mice. b-Actin was used as a
loading control. mRNA expression of glutathione S-transferase (Gst) and
glutamate cysteine ligase catalytic subunit (Gclc) (C) and GSH concentra-
tions (D) in WT and Mrp2-null mice. Data are presented as means  SEM.
n Z 4 to 5 (A); n Z 4 to 6 (C and D). mRNA data were normalized to WT
mice. *P < 0.05 compared with naive WT mice.
1303
Figure 6 Characterization of hMRP2 mice. In-
direct immunoﬂuorescence against mMrp2 (EAG15
antibody) or hMrp2 (M2III-6 antibody) (green) was
conducted on 6-mm kidney cryosections from
control WT, Mrp2-null, and hMRP2 mice. Brush
border localization of mMrp2 and hMRP2 proteins
was conﬁrmed by co-localization with mouse Bcrp
protein (mBcrp; Bxp-53 antibody) (red). A:
Representative cortex regions are shown. B: Direct
and total bilirubin concentrations were quantiﬁed
in plasma from control WT, Mrp2-null, and hMRP2
mice. Data are presented as means  SEM. n Z 3
to 5. *P < 0.05 compared with naive WT mice.
Original magniﬁcation, 64 (A).
Wen et altriphosphateedependent transport of CDCF in plasma
membrane vesicles (Figure 1B). Transport of CDCF by both
orthologswas inhibited up to 70% to 80%at 100 to 200mmol/L
cisplatin. mMrp2-mediated transport was also markedly
inhibited at 50 mmol/L cisplatin. Note that serum concentra-
tions as high as 20 mmol/L have been observed clinically,26
although it is unclear how this value translates to intracellular
tubule levels.
Renal and Hepatic Injury
Cisplatin caused time-dependent renal injury in WT and
Mrp2-null mice (Figure 2A). BUN levels increased similarly
in both genotypes on day 3. By 4 days, BUN levels in
cisplatin-treated Mrp2-null mice were twofold higher than
those in WT mice. Likewise, elevations in serum creatinine
levels were observed only on day 4, with a greater increase
in Mrp2-null mice. Mild increases in alanine aminotrans-
ferase activity were also seen in cisplatin-treated Mrp2-null
mice, with no change detected in WT mice.
Cisplatin-treated Mrp2-null mice exhibited signiﬁcant
elevations in the renal mRNA expression of kidney injury
molecule-1 (fourfold), metallothionein-1 (twofold), and
heme oxygenase-1 (2.5-fold) on day 4 compared with WT
mice (Figure 2B). In addition, Mrp2-null mice had a 44%
reduction in urine output between 3 and 4 days, although
this decrease was not statistically signiﬁcant (Figure 2C).
Histopathologic evaluation of kidneys from cisplatin-
treated mice revealed S1/S2 proximal tubule degeneration
and necrosis as well as sloughing of tubule epithelium that1304was more severe in Mrp2-null mice at 4 days (Figure 3 and
Table 2). Necrotic tubules contained renal casts with eosin-
ophilic material and were more numerous inMrp2-null mice.
Livers from WT and Mrp2-null mice showed no evidence of
hepatocellular degeneration and/or necrosis (data not shown).
Pt Concentrations
Kidney concentrations of Pt in Mrp2-null mice were
elevated above WT levels at 24 and 48 hours (30% increase
in the area under the curve) (Figure 4A). Similar to the
kidneys, Pt concentrations were higher in the livers of
Mrp2-null mice through 72 hours. The clearance of Pt from
the plasma was similar between WT and Mrp2-null mice,
suggesting similar uptake between genotypes. Using meta-
bolic cages, total Pt excretion into urine was high and var-
iable in both genotypes at 24 hours and decreased by 48 and
72 hours, with no differences observed (Figure 4A). Frac-
tionation of kidneys from WT and Mrp2-null mice 24 hours
after cisplatin treatment revealed 50% increases in Pt levels
in cytosol and DNA but not in the crude membrane fraction,
suggesting speciﬁcity in the subcellular localization of
cisplatin intermediates and/or adducts (Figure 4B).
Kidney Uptake and Efﬂux Transporters
Because additional proteins can transport cisplatin, we
quantiﬁed the basal expression of Oct2, Ctr1, and Mate1
mRNAs and proteins as well as additional apical efﬂux
transporters, Mrp4, Bcrp, and multidrug resistance protein 1ajp.amjpathol.org - The American Journal of Pathology
Figure 7 Renal and hepatic injury markers in WT, Mrp2-null, and hMRP2 mice treated with cisplatin. A: BUN, serum creatinine (SCr), and alanine
aminotransferase (ALT) levels in plasma from WT, Mrp2-null, and hMRP2 mice 4 days after 20-mg/kg i.p. cisplatin treatment. B: mRNA expression of kidney
injury molecule-1 (Kim-1), metallothionein-1 (Mt-1), and heme oxygenase-1 (Ho-1) was quantiﬁed using total kidney RNA from control and 20 mg/kg cis-
platinetreated WT and Mrp2-null mice on day 4. Data are presented as means  SEM. nZ 3 to 9 (A and B) *P < 0.05 compared with genotype control mice;
yP < 0.05 compared with cisplatin-treated WT mice.
MRP2 Protects Against Cisplatin Toxicityin both genotypes. Expression of Oct2, Ctr1, Mate1, Bcrp,
and multidrug resistance protein 1 mRNA and protein was
similar in kidneys from naive WT and Mrp2-null mice
(Figure 5, A and B). Because of the high expression of Oct1
mRNA in mice,27 mRNA levels of this isoform were also
assessed and unchanged in Mrp2-null mice (Figure 5A).
Oct3 mRNA levels were very low in both genotypes (data
not shown). Mrp4 mRNA and protein levels were elevated
in Mrp2-null mice, similar to previous reports.28,29 It is
unclear whether Mrp4 can transport cisplatin; however, this
basal increase does not seem to compensate for reduced Pt
excretion and enhanced toxicity in Mrp2-null mice.
Kidney GSH Pathways
Basal differences in the mRNA expression of enzymes
involved in GSH production and conjugation were also
quantiﬁed. Compared with WT mice, expression of Gsta3,
p1/2, and m1 was elevated 50% to 100% in kidneys from
naive Mrp2-null mice (Figure 5C). There were no notable
differences in Gstt1 and glutamate cysteine ligase catalytic
subunit mRNA levels between genotypes. Renal GSH
concentrations were not signiﬁcantly different between WT
and Mrp2-null mice (Figure 5D).
hMRP2 Mice
hMRP2 mice have been recently generated as a transgenic
knock-in in Mrp2-null mice.30 To conﬁrm proper trafﬁckingThe American Journal of Pathology - ajp.amjpathol.orgof hMRP2 protein to the brush border membrane of tu-
bules, we used species-speciﬁc antibodies against Mrp2/
MRP2 for co-localization with the mouse Bcrp transporter
(Figure 6A). As expected, the anti-rodent Mrp2 antibody
detected protein in WT mice only, which co-localized with
mouse Bcrp on the apical membrane of tubules. The anti-
human MRP2 antibody detected MRP2 protein in tubules
that co-localized with mouse Bcrp in the humanized mice.
Neither mMrp2 nor hMRP2 protein was detected in
the Mrp2-null mice. Similar insertion of hMRP2 protein
into the canalicular membrane of hepatocytes was seen
in humanized mice (Supplemental Figure S1). Bilirubin is
a known Mrp2/MRP2 substrate. Similar to patients
with Dubin-Johnson syndrome, mice lacking Mrp2 have
increased direct and total bilirubin levels.28,29 We simi-
larly observed hyperbilirubinemia in Mrp2-null mice that
was reduced in humanized mice (Figure 6B), conﬁrming
that the hMRP2 protein is functional in the transgenic
animals.
Similar to Figure 2, administration of cisplatin to Mrp2-
null mice increased BUN, serum creatinine, and alanine
aminotransferase levels as well as kidney injury molecule-1
and heme oxygenase-1 mRNA levels to a greater extent than
in WT mice (Figure 7). Expression of MRP2 in humanized
mice restored these end points to levels observed in WT
mice. Likewise, Pt levels were 41% higher in the kidneys
of Mrp2-null mice compared with WT and hMRP2 mice
(Figure 8A). No differences in plasma Pt levels were
detected between genotypes (Figure 8B).1305
Figure 8 Pt concentrations in WT, Mrp2-null, and hMRP2 mice treated
with cisplatin. Pt concentrations were quantiﬁed by inductively coupled
plasma mass spectrometry in the kidneys (A) and plasma (B) of WT, Mrp2-
null, and hMRP2 mice 24 hours after treatment with 20 mg/kg of i.p.
cisplatin. Data are presented as means  SEM. n Z 6 to 9 (A and B).
*P < 0.05 from cisplatin-treated WT mice.
Figure 9 Proposed metabolism and transport of cisplatin renal proximal
tubules. Cisplatin is removed from the blood by OCT2 and CTR1. Cisplatin
can then be excreted by MATE1. Cisplatin also hydrolyzes spontaneously to
aquated species that can bind DNA and cause toxicity or that can be
conjugated with GSH by glutathione S-transferases (GSTs). We propose that
the MRP2 efﬂuxes cisplatin-GSH to the tubule lumen, where it can be
cleaved by g-glutamyltranspeptidase (GGT) and aminodipeptidase (AP) to
cisplatin-cysteine (CYS). The cisplatin-CYS conjugate is then reabsorbed by
the proximal tubule through an unknown mechanism. Cisplatin-CYS can
then be metabolized by cysteine S-conjugate b-lyase (BL) to form a reac-
tive thiol that contributes to toxicity.
Wen et alDiscussion
We investigated the role of Mrp2 in the disposition and
toxicity of cisplatin in mice. We have shown enhanced
susceptibility of Mrp2-null mice to renal injury by multiple
end points (histopathology, serum analytes, urine output,
and biomarker mRNAs). Differences in toxicity are likely
due to higher concentrations of Pt in the kidneys of Mrp2-
null mice. It can be suggested that elevated tissue Pt con-
centrations are due to impaired efﬂux rather than enhanced
uptake because levels of Oct2 and Ctr1 mRNA and protein
as well as Pt clearance from plasma were similar between
genotypes. The present ﬁndings are in contrast to a recent
study that concluded that Mrp2 does not participate in the
renal excretion and toxicity of cisplatin in mice.31 This
conclusion was based on histopathological evaluation and
urinary Pt concentrations in cisplatin-treated WT and Mrp2-
null mice at 3 days. Note that these data are consistent with
the present ﬁndings because we did not observe differences
in renal injury between genotypes until 4 days. Likewise,
quantiﬁcation of Pt concentrations in the kidneys and liver
may be a more sensitive measure of pharmacokinetics in
mice. These ﬁndings strongly support the use of time course
studies for comparison of toxicity end points. Furthermore,
these data are consistent with previous in vitro studies
demonstrating a role for MRP2 in cytoprotection against
cisplatin in isolated hepatocytes,19 esophageal squamous1306carcinoma cells,32 and hepatocellular carcinoma cells33 but
extends this function to normal kidneys.
Cisplatin-GSH is proposed to be metabolized by g-glu-
tamyltranspeptidase to a cysteinyl-glycine conjugate and
aminopeptidase to a cysteine conjugate on the extracellular
surface of the brush border membrane (Figure 9).34e36 The
cysteine conjugates are then transported into proximal tu-
bules and are metabolized by b-lyase to highly reactive
thiols. The mechanism(s) for cisplatin conjugate reabsorp-
tion is not well-known. Neutral amino acid transporter
complexes, such as system L, may mediate inﬂux, similar to
observations in carcinoma cells.37 However, additional ex-
periments are needed to identify the exact carriers involved
in intact proximal tubules.
Although conjugation with GSH is generally a detoxiﬁ-
cation reaction, cisplatin conjugated to GSH, cysteinyl-
glycine, and N-acetylcysteine is more toxic to cultured
LLC-PK1 kidney cells than cisplatin itself.34 This is further
supported by studies demonstrating that pharmacological
inhibition of g-glutamyltranspeptidase and b-lyase protects
mice from nephrotoxicity35,36 and that g-glutamyl-
transpeptidaseenull mice are resistant to cisplatin injury.35
Because of the important role of GSH conjugation in the
formation of reactive Pt metabolites, the higher expression of
Gsts, despite similar GSH levels in Mrp2-null mice, may
contribute to the higher susceptibility of these mice to
cisplatin toxicity. Therefore, as more sensitive technologiesajp.amjpathol.org - The American Journal of Pathology
MRP2 Protects Against Cisplatin Toxicityfor detecting cisplatin conjugates in vivo are developed, it
will be important to identify the cisplatin species that are
retained in the cytosol of Mrp2-null mice.
The hMRP2 protein trafﬁcs to the brush border and
canalicular membranes and restores normal circulating
bilirubin concentrations in Mrp2-null mice.30 We have
demonstrated that hMRP2 mice have a similar susceptibility
to cisplatin nephrotoxicity as WT mice. In fact, BUN and
serum creatinine levels were slightly lower in hMRP2 mice.
This may be due to the higher MRP2 mRNA level in hu-
manized mice compared with WT mice.30 The ability of
hMRP2 to protect against the toxicity of various pharma-
ceuticals has been demonstrated in multiple tissues based on
single nucleotide polymorphism analyses. For example,
hMRP2 polymorphisms alter the sensitivities of individuals
to tenofovir nephrotoxicity,38 irinotecan-induced diarrhea,39
doxorubicin-induced cardiotoxicity,40 and carbamezepine-
induced neurotoxicity.41 A preliminary investigation re-
vealed that MRP2 polymorphisms do not predict cisplatin
pharmacokinetics and toxicity; however, this study was
underpowered, and few variants were detected in the study
population.31 Although nephrotoxicity was not evaluated, a
polymorphism in the MRP2 gene has been shown to predict
greater cisplatin efﬁcacy in patients with nonesmall cell
lung cancer.42 Based on these ﬁndings, further work is
needed to investigate MRP2 polymorphisms in predicting
cisplatin efﬁcacy and toxicity.
We observed elevated Pt concentrations in the kidneys
and livers of Mrp2-null mice compared with WT mice
(Figure 4A). In fact, the higher hepatic Pt concentrations
persisted through 72 hours. The ability of the kidneys to ul-
timately excrete the Pt inMrp2-null mice at a faster rate than
the liver may reﬂect the higher expression ofMate1mRNA in
the kidneys.43 The greater hepatic burden of Pt in the livers of
Mrp2-null mice did not result in toxicity. Although mild in-
creases in serum alanine aminotransferase activity were
observed between 3 and 4 days in the null mice, no histo-
pathologic changes consistent with hepatocyte degeneration
or necrosis were observed. This difference in organ sensi-
tivity to cisplatin may reﬂect the unique ability of the kidneys
to generate reactive thiols via b-lyaseemediated metabolism
or possibly enhanced detoxiﬁcation mechanisms in the liver.
The present data add to the existing literature regarding
the transporters that participate in the renal disposition and
toxicity of cisplatin (Figure 9). In conclusion, the absence of
Mrp2 exacerbates cisplatin-induced nephrotoxicity in mice
due to elevated concentrations of Pt in the DNA and cytosol,
and possibly due to enhanced Gst mRNA expression.
Moreover, the MRP2 gene protects Mrp2-null mice from
cisplatin toxicity, demonstrating a renoprotective role for the
human ortholog in vivo.
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